JP2003533489A5 - - Google Patents

Download PDF

Info

Publication number
JP2003533489A5
JP2003533489A5 JP2001583799A JP2001583799A JP2003533489A5 JP 2003533489 A5 JP2003533489 A5 JP 2003533489A5 JP 2001583799 A JP2001583799 A JP 2001583799A JP 2001583799 A JP2001583799 A JP 2001583799A JP 2003533489 A5 JP2003533489 A5 JP 2003533489A5
Authority
JP
Japan
Prior art keywords
composition
microorganism
adjuvant
commensal
mucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001583799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533489A (ja
JP5567756B2 (ja
Filing date
Publication date
Priority claimed from AUPQ7612A external-priority patent/AUPQ761200A0/en
Application filed filed Critical
Publication of JP2003533489A publication Critical patent/JP2003533489A/ja
Publication of JP2003533489A5 publication Critical patent/JP2003533489A5/ja
Application granted granted Critical
Publication of JP5567756B2 publication Critical patent/JP5567756B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001583799A 2000-05-19 2001-05-21 粘膜感染症の処置のための組成物および方法 Expired - Fee Related JP5567756B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU7612 1994-08-24
AUPQ7612A AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections
AUPQ7612 2000-05-19
PCT/AU2001/000588 WO2001087332A1 (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012080832A Division JP2012153706A (ja) 2000-05-19 2012-03-30 粘膜感染症の処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2003533489A JP2003533489A (ja) 2003-11-11
JP2003533489A5 true JP2003533489A5 (enExample) 2008-07-10
JP5567756B2 JP5567756B2 (ja) 2014-08-06

Family

ID=3821690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001583799A Expired - Fee Related JP5567756B2 (ja) 2000-05-19 2001-05-21 粘膜感染症の処置のための組成物および方法
JP2012080832A Pending JP2012153706A (ja) 2000-05-19 2012-03-30 粘膜感染症の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012080832A Pending JP2012153706A (ja) 2000-05-19 2012-03-30 粘膜感染症の処置のための組成物および方法

Country Status (10)

Country Link
US (1) US8637051B2 (enExample)
EP (1) EP1305042B1 (enExample)
JP (2) JP5567756B2 (enExample)
KR (1) KR20030019389A (enExample)
CN (1) CN1437480A (enExample)
AT (1) ATE535284T1 (enExample)
AU (1) AUPQ761200A0 (enExample)
BR (1) BR0110971A (enExample)
CA (1) CA2409813C (enExample)
WO (1) WO2001087332A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
US20080044440A1 (en) * 2004-02-18 2008-02-21 Margaret Dunkley Vaccine Formulated For Administration To Mucosa Of The Lungs
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
CN101060858A (zh) * 2004-08-17 2007-10-24 亨特免疫有限公司 确定口服灭活疫苗剂量的方法
WO2006017895A1 (en) * 2004-08-17 2006-02-23 Hunter Immunology Pty Limited Oral killed vaccines and method for providing same
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
EP2547603B1 (en) 2010-03-18 2014-05-07 Eveready Battery Company, Inc. Button cell battery dispenser package
KR101768118B1 (ko) * 2010-06-25 2017-08-14 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 기도 감염의 치료를 위한 방법 및 약학 조성물
WO2013028756A1 (en) 2011-08-22 2013-02-28 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
CN106456740B (zh) * 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
WO2024234034A1 (en) * 2023-05-12 2024-11-21 Biomune Pty Ltd Compositions and methods for preventative treatments for mucosal associated ailments

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
JPH0680575A (ja) * 1991-03-05 1994-03-22 Meiji Milk Prod Co Ltd 経口免疫賦活剤
AU724743B2 (en) 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
WO1999012416A1 (en) * 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
US6153182A (en) 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
MXPA00006168A (es) * 1997-12-23 2005-02-24 Genesis Res & Dev Corp Ltd Composiciones derivadas de mycrobacterium vaccae y metodos para su uso.
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
SE9800615D0 (sv) * 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
JP2002505302A (ja) 1998-03-05 2002-02-19 ザ メディカル カレッジ オブ オハイオ Il−12の鼻腔内イノキュレーションによる免疫の増強
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
WO2000000218A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
BR0111785A (pt) * 2000-06-19 2003-05-20 Candivax Pty Ltd Composições e métodos para tratamento de candidìase
AU2001284558B2 (en) * 2000-08-08 2007-01-04 Genesis Research And Development Corporation Limited Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them

Similar Documents

Publication Publication Date Title
Mayr et al. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157: H7 bacterial ghosts protects mice against lethal challenge
JP2012153706A (ja) 粘膜感染症の処置のための組成物および方法
US20030180260A1 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
Teanpaisan et al. Lactobacillus paracasei SD1, a novel probiotic, reduces mutans streptococci in human volunteers: a randomized placebo-controlled trial
WO2000056359A3 (en) Vaccine against streptococcus pneumoniae
CA2437899A1 (en) Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
JP2018520677A5 (enExample)
AU2007316091B2 (en) Prophylactic tuberculosis vaccine
JP2001514233A5 (enExample)
NO933037L (no) Fremstilling og anvendelse av formalinavlivede e. coliorganismer som uttrykker kolonisasjonsfaktor-antigen (cfa), til vaksinasjon mot tarminfeksjon/diare hos mennesker foraarsaket av tarmtoksigenet e. coli-bakterier
Kyd et al. Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview
JP2006519217A5 (enExample)
AU2001258060B2 (en) Compositions and methods for treatment of mucosal infections
Silvan et al. Modulation of inflammation and oxidative stress in Helicobacter pylori infection by bioactive compounds from food components
JP2007512815A (ja) 微生物用の凍結保護剤
Stjernquist-Desatnik et al. Protective effect of heterologous gram-positive vaccine against lethal upper respiratory tract infection with type M50 group A streptococci in mice
Wainwright Biological control of microbial infections and cancer in humans: Historical use to future potential
Nikolov Probiotics and mucosal immune response
AU2001258060A1 (en) Compositions and methods for treatment of mucosal infections
JP2008509936A5 (enExample)
AU2001265695A1 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
Challenge Bacterial Ghosts as an Oral Vaccine
Reismaa Piimhappebakterite mõju inimese tervisele
AR030326A1 (es) UNA COMPOSICION DE VACUNA PARA LA PREVENCIoN DE INFECCIONES PULMONARES Y MÉTODO PARA SU ELABORACIoN
TH57768A (th) วัคซีนเชื้อซัลโมเนลลา(Salmonella vaccine)